As we continue our mission of delivering high-quality oncology news, analysis, and updates, we're pleased to present a new interactive and educational resource center, http://WKOncology.com. This debut content gateway is dedicated to renal cell carcinoma (RCC).
Available online now, you'll find regularly updated articles on topics such as "First-line Therapy for Treatment Naive Patients," "Era36 Expression in Renal Tumors," and "Implications for the Classification of PEComas and the Differential Diagnosis With Metastatic Renal Cell Carcinoma," to name a few. And of course the latest FDA updates are included, such as the recent approval of cabozantinib (Cabometyx) for the treatment of advanced renal cell carcinoma in patients who have received prior anti-angiogenic therapy.
What's more, http://WKOncology.com features expert video commentary from renowned RCC authorities who share perspective on game changers in RCC developments, research and funding activities, and more. And Michael Harrison, MD, Assistant Professor of Medicine, Duke Cancer Institute, provides an exclusive and timely blog on the latest RCC trends.
http://WKOncology.com also provides you invaluable access to the Renal Cell Carcinoma 5 Minute Consult as well as information you can share with your patients, the "Understanding Kidney Cancer" anatomical chart. We invite you to test your RCC knowledge with the interactive Expert Q&A. Simply read the scenario, select from a list of possible responses, and the correct answer (with explanation) will appear.
To complete the package and take the WKOncology Renal Cell Carcinoma Resource Center one step further, we'll also include four digital magazine editions. An easily identified icon for this traditional magazine in a digital format will be an option on the homepage. The first digital edition includes the latest RCC information and study results garnered from the American Society of Clinical Oncology meeting in June.
As the content and features will be updated weekly, we encourage you to visit http://WKOncology.com often. We welcome input, feedback and comments on this exciting new initiative.